Merck and GSK about to lose market share to Rotavac, a bovine-based rotavirus vaccine developed in India that can be sold far cheaper than GSK or Merck's drugs. You know who has the leading, bovine-based Shigella/ETEC vaccine candidate already on market in form of Travelan (and can be produced on the cheap)....that's right ....US. US baby. Immuron. Nobody else.
See you at the buyout in 2019 or 2020.
Merck the Likely Buyer of Immuron, GSK Second, page-2
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 61502 | 1 |
View Market Depth
| Last trade - 11.35am 13/11/2024 (20 minute delay) ? |
| IMC (ASX) Chart |
Day chart unavailable